Overview
The marketing authorisation for Zalmoxis has been withdrawn at the request of the marketing authorisation holder.
Zalmoxis : EPAR - Summary for the public
English (EN)
(654.49 KB - PDF)View
български (BG)
(760.89 KB - PDF)
español (ES)
(653.89 KB - PDF)
čeština (CS)
(733.96 KB - PDF)
dansk (DA)
(653.11 KB - PDF)
Deutsch (DE)
(655.77 KB - PDF)
eesti keel (ET)
(650.21 KB - PDF)
ελληνικά (EL)
(765.42 KB - PDF)
français (FR)
(655.08 KB - PDF)
hrvatski (HR)
(664.62 KB - PDF)
italiano (IT)
(652.81 KB - PDF)
latviešu valoda (LV)
(715.93 KB - PDF)
lietuvių kalba (LT)
(669.25 KB - PDF)
magyar (HU)
(727.73 KB - PDF)
Malti (MT)
(717.66 KB - PDF)
Nederlands (NL)
(653.86 KB - PDF)
polski (PL)
(733.21 KB - PDF)
português (PT)
(653.34 KB - PDF)
română (RO)
(668.59 KB - PDF)
slovenčina (SK)
(732.91 KB - PDF)
slovenščina (SL)
(726.58 KB - PDF)
Suomi (FI)
(652.21 KB - PDF)
svenska (SV)
(651.83 KB - PDF)
Product information
Zalmoxis : EPAR - Product Information
English (EN)
(1.09 MB - PDF)View
български (BG)
(1.71 MB - PDF)
español (ES)
(1.04 MB - PDF)
čeština (CS)
(1.62 MB - PDF)
dansk (DA)
(856.94 KB - PDF)
Deutsch (DE)
(939.53 KB - PDF)
eesti keel (ET)
(1.05 MB - PDF)
ελληνικά (EL)
(1.86 MB - PDF)
français (FR)
(1.06 MB - PDF)
hrvatski (HR)
(1.19 MB - PDF)
íslenska (IS)
(1.03 MB - PDF)
italiano (IT)
(1.09 MB - PDF)
latviešu valoda (LV)
(1.64 MB - PDF)
lietuvių kalba (LT)
(1.12 MB - PDF)
magyar (HU)
(1.62 MB - PDF)
Malti (MT)
(1.65 MB - PDF)
Nederlands (NL)
(1004.44 KB - PDF)
norsk (NO)
(1.08 MB - PDF)
polski (PL)
(1.63 MB - PDF)
português (PT)
(1.04 MB - PDF)
română (RO)
(1.12 MB - PDF)
slovenčina (SK)
(1.62 MB - PDF)
slovenščina (SL)
(1.64 MB - PDF)
Suomi (FI)
(1.16 MB - PDF)
svenska (SV)
(913.58 KB - PDF)
Latest procedure affecting product information: II/0009/G
26/07/2018
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Zalmoxis : EPAR - All Authorised presentations
English (EN)
(577.05 KB - PDF)View
български (BG)
(620.06 KB - PDF)
español (ES)
(577.71 KB - PDF)
čeština (CS)
(608.26 KB - PDF)
dansk (DA)
(577.54 KB - PDF)
Deutsch (DE)
(577.51 KB - PDF)
eesti keel (ET)
(577.67 KB - PDF)
ελληνικά (EL)
(619.96 KB - PDF)
français (FR)
(577.52 KB - PDF)
hrvatski (HR)
(591.71 KB - PDF)
íslenska (IS)
(577.59 KB - PDF)
italiano (IT)
(577.7 KB - PDF)
latviešu valoda (LV)
(610.12 KB - PDF)
lietuvių kalba (LT)
(594.87 KB - PDF)
magyar (HU)
(599.51 KB - PDF)
Malti (MT)
(611.06 KB - PDF)
Nederlands (NL)
(577.31 KB - PDF)
norsk (NO)
(577.68 KB - PDF)
polski (PL)
(609.04 KB - PDF)
português (PT)
(577.7 KB - PDF)
română (RO)
(592.97 KB - PDF)
slovenčina (SK)
(600.14 KB - PDF)
slovenščina (SL)
(605.32 KB - PDF)
Suomi (FI)
(577.43 KB - PDF)
svenska (SV)
(577.6 KB - PDF)
Product details
- Name of medicine
- Zalmoxis
- Active substance
- Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)
- International non-proprietary name (INN) or common name
- allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)
- Therapeutic area (MeSH)
- Hematopoietic Stem Cell Transplantation
- Graft vs Host Disease
- Anatomical therapeutic chemical (ATC) code
- L01
Pharmacotherapeutic group
Antineoplastic agentsTherapeutic indication
Zalmoxis is indicated as adjunctive treatment in haploidentical haematopoietic stem cell transplantation (HSCT) of adult patients with high-risk haematological malignancies.
Assessment history
Zalmoxis : EPAR - Procedural steps taken and scientific information after authorisation
English (EN)
(650.45 KB - PDF)View
This page was last updated on